ArticleClinical epigenetics2011
Molecular marks for epigenetic identification of developmental and cancer stem cells.
Article in Clinical epigenetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Cytokines, Signaling and Epigenetic Mechanisms: Shaping the Acute Lymphoblastic Leukemia Microenvironment.Cells · 2026Review
- The role of epigenetics in cancer: From pathways to the clinic.Journal of family medicine and primary care · 2025Review
- KLF4 is an epigenetically modulated, context-dependent tumor suppressor.Frontiers in cell and developmental biology · 2024Review
- Observational
- SOX2 and BCL-2 Expressions in Odontogenic Keratocyst and Ameloblastoma.Medicina oral, patologia oral y cirugia bucal · 2020Article
- Villi development core-related gene expression associated with lung squamous cancer prognosis.Medicine · 2019Article
- Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Silencing of ZRF1 impedes survival of estrogen receptor positive MCF-7 cells and potentiates the effect of curcumin.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Epigenetic alterations in patients with type 2 diabetes mellitus.Balkan journal of medical genetics : BJMG · 2015Article
- Review
- Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer.Cellular and molecular life sciences : CMLS · 2014Review
- Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer.Clinical epigenetics · 2014Article
- Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2014Review
- The putative promoters of germ cell-specific genes and Nanog are hypomethylated in chicken sperm.The Journal of reproduction and development · 2014Article
- Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.Clinical epigenetics · 2013Article
- New gene signatures for pediatric brain tumors: a step forward in the understanding of molecular basis of CNS PNET.Translational pediatrics · 2013Article
- An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function.Epigenetics · 2012Review
- 5-Aza-2'-deoxycytidine stress response and apoptosis in prostate cancer.Clinical epigenetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledEpigenetic regulations of genes by reversible methylation of DNA (at the carbon-5 of cytosine) and numerous reversible modifications of histones play important roles in normal physiology and development, and epigenetic deregulations are associated with developmental disorders and various disease states, including cancer. Stem cells have the capacity to self-renew indefinitely. Similar to stem cells, some malignant cells have the capacity to divide indefinitely and are referred to as cancer stem cells. In recent times, direct correlation between epigenetic modifications and reprogramming of stem cell and cancer stem cell is emerging. Major discoveries were made with investigations on reprogramming gene products, also known as master regulators of totipotency and inducer of pluoripotency, namely, OCT4, NANOG, cMYC, SOX2, Klf4, and LIN28. The challenge to induce pluripotency is the insertion of four reprogramming genes (Oct4, Sox2, Klf4, and c-Myc) into the genome. There are always risks of silencing of these genes by epigenetic modifications in the host cells, particularly, when introduced through retroviral techniques. In this contribution, we will discuss some of the major discoveries on epigenetic modifications within the chromatin of various genes associated with cancer progression and cancer stem cells in comparison to normal development of stem cell. These modifications may be considered as molecular signatures for predicting disorders of development and for identifying disease states. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13148-010-0016-0) contains supplementary material, which is available to authorized users.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.